• Press Release

BIA reacts to proposed IP waiver for COVID-19 vaccines

Steve Bates OBE, Chief Executive of the Bioindustry Association said: “This is not a panacea. Just handing countries governments a recipe book without the ingredients, safeguards, infrastructure, and sizable workforce with the high skills needed to deliver safe and effective vaccines, will not speedily deliver help to all those that need it.

2021 on track to be another record-breaking year for UK biotech investment as investors see returns from the maturing sector

UK biotech companies are on track for a record-breaking year of fundraising according to the latest data released by the UK BioIndustry Association (BIA) and Clarivate. More than £830m in fresh capital was raised in the three months to the end of February, almost topping the £894m raised in the first six months of 2020, which itself was a record-breaking year.

BIA welcomes £1bn investment deal and launch of Life Sciences Investment Programme

Steve Bates OBE, Chief Executive of the BioIndustry Association said: “Congratulations to the Government’s new Office for Investment for securing the £1 billion UAE-UK Sovereign Investment Partnership, which I am delighted to see focused on the opportunities in UK life sciences.

BIA urges the Government to take a science-based approach to regulation of gene editing and GMOs

The BioIndustry Association (BIA) has urged the Government to adopt a science-based and innovation-friendly regulatory framework for gene editing and genetically modified organisms (GMOs).

BIA welcomes updated guidance from the MHRA on approved countries for batch testing

The BioIndustry Association (BIA) has welcomed updated guidance from the MHRA published today which makes changes to the list of approved countries for batch testing and the importation of medicines.

BIA reacts to £42m investment into Touchlight

Reacting to the news  of Touchlight's £42m investment round, Steve Bates OBE, Chief Executive of the BioIndustry Association said: “UK biotech and life sciences companies have been at the heart of understanding, supporting and leading the manufacture and scale up of COVID-19 vaccines. The investment into Touchlight will give the UK further manufacturing capability in mRNA vaccines and in the innovative field of cell and gene therapies, which will benefit UK patients enormously in the years to come.”

BIA reacts to eXmoor pharma investment

Reacting to new that eXmoor pharma has secured £12m of investment, Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said:  “This is great news for UK medicine manufacturing. The investment into eXmoor’s cutting edge process development and clinical manufacturing in the south west of England will create long term highly skilled jobs. Anchoring next generation scale up and manufacturing in the UK will help ensure NHS patients will be amongst the first to benefit from new gene therapies as they develop in the coming years.”

BIA responds to 2021 Budget

Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA), said: "The COVID-19 pandemic has shown the strategic necessity for the UK to have a thriving domestic life sciences and biotech sector. Companies and researchers from across the UK have led in the global effort to develop, manufacture and deploy the COVID-19 vaccines, therapies and diagnostics needed to re-open the global economy. As the Prime Minister made clear last week, this successful public-private partnership is the formula for our country’s prosperity for years to come, a strong and active government investing massively in science and technology, coupled with a dynamic enterprise economy.

BIA welcomes the establishment of Advanced Research and Invention Agency (ARIA)

Responding to the Government’s announcement of ARIA today, Ruth McKernan CBE, Chair of the BIA Board and Venture Partner at SV Health Investors said:

Dr David Atkins joins the National Genomics Board as the BIA SME representative

Dr David Atkins, Chief Executive Officer of Congenica, has joined the National Genomics Board as the BioIndustry Association (BIA)’s SME representative. The Board brings together senior decision makers from government, the NHS, academia and industry to advise the UK Government on its national genomics strategy, Genome UK. Dr Atkins’ appointment to the Board means that the voice of genomic start-ups and SMEs will be heard at the highest levels of government.